


CLAIMS

We claim:

1. A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein

Y is

- a) -NHC(=W)R^2 , or
- b) -O-het , -S-het , or -NH-het ;

W is

- a) O, or
- b) S;

X is

- a) -S(=O)_m , or
- b) -CHR^3 ;

R^1 is

- a) C_{1-8} alkyl,
- b) -C(=O)R^4 , or
- c) -C(=S)NHC_{1-4} alkyl;

R^2 is

- a) H,
- b) C_{1-6} alkyl,
- c) cyclopropyl,
- d) -OC_{1-4} alkyl,
- e) -NH_2 ,
- f) -NHC_{1-6} alkyl, or
- g) $\text{-N(C}_{1-6}\text{ alkyl)}_2$;

R^3 is H, or C_{1-4} alkyl;

R^4 is

- a) H,

- b) C₁₋₆ alkyl,
 c) -CH₂OC(=O)C₁₋₄ alkyl;

at each occurrence above, alkyl is optionally substituted with one or more R⁵;


R⁵ is

- 5 a) halo,
 b) CN,
 c) NO₂,
 d) C₁₋₆ alkyl,
 e) phenyl,
 10 f) OR⁶,
 g) C(=O)R⁶,
 h) OC(=O)R⁶,
 i) C(=O)OR⁶,
 j) S(=O)_mR⁶,
 15 k) S(=O)_mNR⁶R⁶,
 l) NHC(=O)R⁶,
 m) C(=O)NR⁶R⁶,
 n) NR⁶R⁶,

R⁶ is independently H, C₁₋₆alkyl, phenyl, or het;


- 20 het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring; wherein het is optionally substituted with one or more halo, CN, NO₂, C₁₋₆ alkyl, OR⁶, phenyl, S(=O)_mR⁶, C(=O)R⁶, OC(=O)R⁶, NHC(=O)R⁶, or NR⁶R⁶, oxo, or oxime;
 25 m is 0, 1 or 2; and n is 1 or 2.

2. A compound of claim 1 which is a compound of formula IA



IA.

- 30 3. A compound of claim 1 which is a compound of formula IB



IB.

4. A compound of claim 2 or 3 wherein R² is C₁₋₆alkyl.
- 5
5. A compound of claim 2 or 3 wherein R² is methyl.
6. A compound of claim 2 or 3 wherein R¹ is formyl or acetyl.
- 10 7. A compound of claim 2 or 3 wherein n is 1.
8. A compound of claim 2 or 3 wherein n is 2.
- 15 9. A compound of claim 2 or 3 wherein R¹ is 2-fluoroethyl, glycolyl, methoxyacetyl, oxoethylacetate, or methylaminocarbothioyl.
10. A compound of claim 2, wherein R³ is methy.
- 20 11. A compound of claim 1 which N-{[4-(N-formyl-2-methylindolinyl)-5-oxo-isoxazol-2-yl]methyl}acetamide.
12. A compound of claim 1 where in het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.
- 25 13. A method for treating microbial infections in patients comprising: administering to a human or warm blood animals in need thereof an effective amount of a compound of claim 1.
- 30 14. The method of claim 13 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

15. The method of claim 13 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

16. The method of claim 13 wherein said compound is administered in an amount of
5 from about 1 to about 50 mg/kg of body weight/day.

17. A method for treating microbial infections of claim 13 wherein the infection is skin infection.

10 18. A method for treating microbial infections of claim 13 wherein the infection is eye infection.

19. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

15